Skip to main content

Advertisement

SpringerLink
Log in

Different Efflux Transporter Affinity and Metabolism of 99mTc-2-Methoxyisobutylisonitrile and 99mTc-Tetrofosmin for Multidrug Resistance Monitoring in Cancer

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Background

Little is known about the affinity and stability of 99mTc-labeled 2-methoxyisobutylisonitrile (99mTc-MIBI) and tetrofosmin (99mTc-TF) for imaging of multiple drug resistance transporters in cancer. We examined the affinity of 99mTc-labeled compounds for these transporters and their stability.

Methods

99mTc-MIBI and 99mTc-TF were incubated in vesicles expressing P-glycoprotein (MDR1), multidrug resistance-associated protein (MRP)1–4, or breast cancer resistance protein with and without verapamil (MDR1 inhibitor) or MK-571 (MRP inhibitor). Time activity curves of 99mTc-labeled compounds were established using SK-N-SH neuroblastoma, SK-MEL-28 melanoma, and PC-3 prostate adenocarcinoma cell lines, and transporter expression of multiple drug resistance was measured in these cells. The stability was evaluated.

Results

In vesicles, 99mTc-labeled compounds had affinity for MDR1 and MRP1. 99mTc-TF had additional affinity for MRP2 and MRP3. In SK-N-SH cells expressing MDR1 and MRP1, MK-571 produced the highest uptake of both 99mTc-labeled compounds. 99mTc-MIBI uptake with inhibitors was higher than 99mTc-TF uptake with inhibitors. 99mTc-TF was taken up more in SK-MEL-28 cells expressing MRP1 and MRP2 than PC-3 cells expressing MRP1 and MRP3. 99mTc-MIBI was metabolized, whereas 99mTc-TF had high stability.

Conclusion

99mTc-MIBI is exported via MDR1 and MRP1 (MRP1 > MDR1) at greater levels and more quickly compared to 99mTc-TF, which is exported via MDR1 and MRP1–3 (MRP1 > MDR1; MRP1, 2 > MRP3). Because 99mTc-MIBI is metabolized, clinical imaging for monitoring MDR and shorter examination times may be possible with an earlier scanning time on late phase imaging. 99mTc-TF has high stability and accurately reflects the function of MDR1 and MRP1–3.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Lockhart A, Tirona L, Kim R. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2:685–98.

    Article  CAS  Google Scholar 

  2. Kailasnath P, Sinusas AJ. Technetium-99m-labeled myocardial perfusion agents: are they better than thallium-201? Cardiol Rev. 2001;9(3):160–72.

    Article  CAS  Google Scholar 

  3. Schillaci O, Spanu A, Madeddu G. [99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPECT and fusion imaging in lung cancer, malignant lymphomas and brain tumors. Q J Nucl Med Mol Imaging. 2005;49(2):133–44.

    CAS  PubMed  Google Scholar 

  4. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergün EL, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998;39:228–34.

    CAS  PubMed  Google Scholar 

  5. Kurata S, Ushijima K, Kawahara A, Kaida H, Kawano K, Hirose Y, et al. Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study. Ann Nucl Med. 2015;29:643–9.

    Article  CAS  Google Scholar 

  6. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977–84.

    CAS  PubMed  Google Scholar 

  7. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, et al. Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function. Eur J Nucl Med Mol Imaging. 2003;30:1529–31.

    Article  CAS  Google Scholar 

  8. Gomes CM, Abrunhosa AJ, Pauwels EK, Botelho MF. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin. Cancer Biother Radiopharm. 2009;24:215–27.

    Article  CAS  Google Scholar 

  9. Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer. 2011;104:707–13.

    Article  CAS  Google Scholar 

  10. O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008;68:5380–9.

    Article  CAS  Google Scholar 

  11. Montani M, Hermanns T, Müntener M, Wild P, Sulser T, Kristiansen G. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Arch. 2013;462:437–43.

    Article  CAS  Google Scholar 

  12. Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31:73–99.

    Article  CAS  Google Scholar 

  13. Kobayashi M, Nakanishi T, Nishi K, Higaki Y, Okudaira H, Ono M, et al. Transport mechanism of hepatic uptake and bile excretion in clinical hepatobiliary scintigraphy with 99mTc-N-pyridoxyl-5-methyltryptophan. Nucl Med Biol. 2014;41:338–42.

    Article  CAS  Google Scholar 

  14. Kobayashi M, Hashimoto F, Ohe K, Nadamura T, Nishi K, Shikano N, et al. Transport mechanism of 11C-labeled L- and D-methionine in human-derived tumor cells. Nucl Med Biol. 2012;39:1213–8.

    Article  CAS  Google Scholar 

  15. Mohamed LA, Kaddoumi A. In vitro investigation of amyloid-β hepatobiliary disposition in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos. 2013;41:1787–96.

    Article  CAS  Google Scholar 

  16. Sakamoto S, Suzuki H, Kusuhara H, Sugiyama Y. Efflux mechanism of taurocholate across the rat intestinal basolateral membrane. Mol Pharm. 2006;3:275–81.

    Article  CAS  Google Scholar 

  17. Reed JR, Backes WL. Formation of P450. P450 complexes and their effect on P450 function. Pharmacol Ther. 2012;133:299–310.

    Article  CAS  Google Scholar 

  18. Japan Radiopharmaceuticals Association: The Minimum Requirements for Radiopharmaceuticals. http://www.houyakkyou.org/img/housha_img/kaisetsu_160630.pdf. Accessed 5 Aug 2018.

  19. Métayé T, Desmarquet M, Rosenberg T, Guilhot J, Bouin-Pineau MH. Rapid quality control for testing the radiochemical purity of 99Tc(m)-tetrofosmin. Nucl Med Commun. 2001;22:1139–44.

    Article  Google Scholar 

  20. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol. 2005;45:689–723.

    Article  CAS  Google Scholar 

  21. Vrachimis A, Hermann S, Máthé D, Schober O, Schäfers M. Systematic evaluation of 99mTc-tetrofosmin versus 99mTc-sestamibi to study murine myocardial perfusion in small animal SPECT/CT. EJNMMI Res. 2012;2:21.

    Article  Google Scholar 

  22. Perek N, Prevot N, Koumanov F, Frere D, Sabido O, Beauchesne P, et al. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol. 2000;27(3):299–307.

    Article  CAS  Google Scholar 

  23. Le Jeune N, Perek N, Denoyer D, Dubois F. Study of monoglutathionyl conjugates TC-99M-sestamibi and TC-99M-tetrofosmin transport mediated by the multidrug resistance-associated protein isoform 1 in glioma cells. Cancer Biother Radiopharm. 2005;20(3):249–59.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wellness Promotion Science Center, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, 920-0942, Japan

    Masato Kobayashi

  2. School of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

    Takafumi Tsujiuchi, Yuya Okui, Asuka Mizutani & Keiichi Kawai

  3. Department of Radioisotope Medicine Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

    Kodai Nishi

  4. School of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

    Takeo Nakanishi & Ikumi Tamai

  5. Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, Chiba, Japan

    Ryuichi Nishii

  6. Graduate School of Medicine, Division of Health Sciences, Osaka University, Osaka, Japan

    Kazuki Fukuchi

  7. Biomedical Imaging Research Center, University of Fukui, Fukui, Japan

    Keiichi Kawai

Authors
  1. Masato Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takafumi Tsujiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuya Okui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Asuka Mizutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kodai Nishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeo Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryuichi Nishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuki Fukuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ikumi Tamai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keiichi Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masato Kobayashi.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, M., Tsujiuchi, T., Okui, Y. et al. Different Efflux Transporter Affinity and Metabolism of 99mTc-2-Methoxyisobutylisonitrile and 99mTc-Tetrofosmin for Multidrug Resistance Monitoring in Cancer. Pharm Res 36, 18 (2019). https://doi.org/10.1007/s11095-018-2548-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11095-018-2548-5

KEY WORDS

Search

Navigation